N4-Acetylcytidine (BioDeep_00000017823)

 

Secondary id: BioDeep_00000015216, BioDeep_00000604286

human metabolite PANOMIX_OTCML-2023 Endogenous blood metabolite


代谢物信息卡片


N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}acetamide

化学式: C11H15N3O6 (285.0961)
中文名称: N-乙酰胞嘧啶
谱图信息: 最多检出来源 Homo sapiens(otcml) 31.16%

Reviewed

Last reviewed on 2024-09-14.

Cite this Page

N4-Acetylcytidine. BioDeep Database v3. PANOMIX ltd, a top metabolomics service provider from China. https://query.biodeep.cn/s/n4-acetylcytidine (retrieved 2025-04-04) (BioDeep RN: BioDeep_00000017823). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

分子结构信息

SMILES: CC(=O)NC1=NC(=O)N(C=C1)C2C(C(C(O2)CO)O)O
InChI: InChI=1S/C11H15N3O6/c1-5(16)12-7-2-3-14(11(19)13-7)10-9(18)8(17)6(4-15)20-10/h2-3,6,8-10,15,17-18H,4H2,1H3,(H,12,13,16,19)/t6-,8-,9-,10-/m1/s1

描述信息

N4-Acetylcytidine is a modified nucleoside. N4-acetylcytidine is an endogenous urinary nucleoside product of the degradation of transfer ribonucleic acid (tRNA); urinary nucleosides are biological markers for patients with colorectal cancer. tRNA has been shown to be excreted in abnormal amounts in the urine of cancer patients. tRNA from neoplastic tissue had a much more rapid turnover rate than the tRNA from the corresponding normal tissue. Evidence indicates that methylation of tRNA occurs only after synthesis of the intact macromolecule. Because there are no specific enzyme systems to incorporate the modified nucleosides into the macromolecular nucleic acid, these nucleosides once released in the process of tRNA turnover cannot be reutilized, nor are they further degraded, but are excreted in urine. (PMID: 15991285, 3506820) [HMDB]
N4-Acetylcytidine is a modified nucleoside. N4-acetylcytidine is an endogenous urinary nucleoside product of the degradation of transfer ribonucleic acid (tRNA); urinary nucleosides are biological markers for patients with colorectal cancer. tRNA has been shown to be excreted in abnormal amounts in the urine of cancer patients. tRNA from neoplastic tissue had a much more rapid turnover rate than the tRNA from the corresponding normal tissue. Evidence indicates that methylation of tRNA occurs only after synthesis of the intact macromolecule. Because there are no specific enzyme systems to incorporate the modified nucleosides into the macromolecular nucleic acid, these nucleosides once released in the process of tRNA turnover cannot be reutilized, nor are they further degraded, but are excreted in urine. (PMID: 15991285, 3506820).
N4-Acetylcytidine is an endogenous metabolite.
N4-Acetylcytidine is an endogenous metabolite.

同义名列表

27 个代谢物同义名

N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}acetamide; N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}acetamide; 4-Acetyl-1-(beta-delta-ribofuranosyl)cytosine; 4-Acetyl-1-(beta-D-ribofuranosyl)cytosine; 4-Acetyl-1-(b-D-ribofuranosyl)cytosine; 4-Acetyl-1-(β-D-ribofuranosyl)cytosine; 4-Acetylcytidine; N4-Acetylcytidine; N-4-Acetylcytidine; N-Acetyl-cytidine; N4-Acetylcytidine; 4-Acetylcytidine; N-Acetylcytidine; Acetylcytidine; 4-N-acetyl-cytidine; Acetamide, N-(1,2-dihydro-2-oxo-1-beta-D-ribofuranosyl-4-pyrimidinyl); C11H15N3O6; Cytidine, N-acetyl-; N-(1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide; N-(1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-2-oxopyrimidin-4-yl)acetamide; N-(1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)acetamide; N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]acetamide; N-Acetylcytidine; 4-Acetylcytidine;; n(4)-acetylcytidine; N4 -Acetylcytidine; N4-Acetyl-D-cytidine; N4-Acetylcytidine, >=98%; n4-Acetylcytidine;n-acetylcytidine



数据库引用编号

13 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Zixiang Geng, Peng Liu, Long Yuan, Kaiyong Zhang, Jiajia Lin, Xiaoli Nie, Huiru Jiang, Bingrong Li, Te Liu, Bimeng Zhang. Electroacupuncture attenuates ac4C modification of P16 mRNA in the ovarian granulosa cells of a mouse model premature ovarian failure. Acupuncture in medicine : journal of the British Medical Acupuncture Society. 2023 02; 41(1):27-37. doi: 10.1177/09645284221085284. [PMID: 35475376]
  • Xinfeng Fei, Yuying Cai, Feng Lin, Yongyi Huang, Te Liu, Yan Liu. Amniotic fluid mesenchymal stem cells repair mouse corneal cold injury by promoting mRNA N4-acetylcytidine modification and ETV4/JUN/CCND2 signal axis activation. Human cell. 2021 Jan; 34(1):86-98. doi: 10.1007/s13577-020-00442-7. [PMID: 33010000]
  • Theresa A Laguna, Cavan S Reilly, Cynthia B Williams, Cole Welchlin, Chris H Wendt. Metabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation. Pediatric pulmonology. 2015 Sep; 50(9):869-77. doi: 10.1002/ppul.23225. [PMID: 26115542]
  • A R Van Rompay, A Norda, K Lindén, M Johansson, A Karlsson. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Molecular pharmacology. 2001 May; 59(5):1181-6. doi: 10.1124/mol.59.5.1181. [PMID: 11306702]
  • J G Tebib, C Reynaud, J P Cedoz, M C Letroublon, A Niveleau. Relationship between urinary excretion of modified nucleosides and rheumatoid arthritis process. British journal of rheumatology. 1997 Sep; 36(9):990-5. doi: 10.1093/rheumatology/36.9.990. [PMID: 9376997]